Drug-induced hyperkalemia.
This is the era of polypharmacy. Treatment with multiple therapeutic agents for multiple underlying medical conditions leads to greater vulnerability to such metabolic imbalances as hyperkalemia. The physician must know which underlying medical conditions and drugs predispose to abnormal intracellular-extracellular potassium balance and abnormal regulation of potassium excretion.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D004232:Diuretics / Q000009:adverse effects; D006493:Heparin / Q000009:adverse effects; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects; D009842:Oligopeptides / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000150:complications; D013722:Teprotide; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004232:Diuretics; D007166:Immunosuppressive Agents; D009467:Neuromuscular Depolarizing Agents; D009842:Oligopeptides; D006493:Heparin; D013722:Teprotide